Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells - PubMed (original) (raw)
Comparative Study
doi: 10.1189/jlb.0604373. Epub 2004 Dec 6.
Affiliations
- PMID: 15582984
- DOI: 10.1189/jlb.0604373
Comparative Study
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells
Bernd Jahrsdörfer et al. J Leukoc Biol. 2005 Mar.
Abstract
Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.
Similar articles
- Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G. Jahrsdörfer B, et al. J Leukoc Biol. 2002 Jul;72(1):83-92. J Leukoc Biol. 2002. PMID: 12101266 - The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z, Guo K, Schluesener HJ. Zhang Z, et al. J Neuroimmunol. 2005 Apr;161(1-2):68-77. doi: 10.1016/j.jneuroim.2004.12.009. J Neuroimmunol. 2005. PMID: 15748945 - Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T, Peschel C. Decker T, et al. Leuk Lymphoma. 2001 Jul;42(3):301-7. doi: 10.3109/10428190109064586. Leuk Lymphoma. 2001. PMID: 11699394 Review. - Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia.
Chen R, Plunkett W. Chen R, et al. Best Pract Res Clin Haematol. 2010 Mar;23(1):155-66. doi: 10.1016/j.beha.2010.01.003. Best Pract Res Clin Haematol. 2010. PMID: 20620979 Review.
Cited by
- In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia.
Hanafy RM, Demian SR, Abou-Shamaa LA, Ghallab O, Osman EM. Hanafy RM, et al. Indian J Hematol Blood Transfus. 2023 Oct;39(4):537-545. doi: 10.1007/s12288-023-01649-y. Epub 2023 Apr 7. Indian J Hematol Blood Transfus. 2023. PMID: 37786827 Free PMC article. - TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, Phillips EH, Burley TA, Mitchell S, Devereux S, Fegan CD, Jones CI, Johnston R, Chevassut T, Schulz R, Seiffert M, Agathanggelou A, Oldreive C, Davies N, Stankovic T, Liloglou T, Pepper C, Pepper AGS. Kennedy E, et al. Blood. 2021 Jun 3;137(22):3064-3078. doi: 10.1182/blood.2020005964. Blood. 2021. PMID: 33512408 Free PMC article. - Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role.
Allegra A, Musolino C, Tonacci A, Pioggia G, Casciaro M, Gangemi S. Allegra A, et al. Cancers (Basel). 2020 Feb 24;12(2):524. doi: 10.3390/cancers12020524. Cancers (Basel). 2020. PMID: 32102441 Free PMC article. Review. - Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators.
Nigar S, Shimosato T. Nigar S, et al. Front Nutr. 2019 Aug 27;6:140. doi: 10.3389/fnut.2019.00140. eCollection 2019. Front Nutr. 2019. PMID: 31508424 Free PMC article. Review. - The regulatory capacity of B cells directs the aggressiveness of CLL.
Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C. Mohr A, et al. Oncoimmunology. 2018 Dec 12;8(3):1554968. doi: 10.1080/2162402X.2018.1554968. eCollection 2019. Oncoimmunology. 2018. PMID: 30723588 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous